EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE

Società Italiana di Emostasi e Trombosi

Bleeding, Thrombosis and Vascular Biology · 16.04.2026 · 5 (s1)

DOI: 10.4081/btvb.2026.554 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bleeding, Thrombosis and Vascular Biology, online erschienen am 16.04.2026. Verfasst von Società Italiana di Emostasi e Trombosi. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims. Combination therapy of atezolizumab and bevacizumab is one of the proposed first-line treatment options for patients with advanced hepatocellular carcinoma (HCC). As a vascular endothelial growth factor inhibitor, bevacizumab increases the risk of gastrointestinal bleeding, particularly in HCC patients with cirrhosis and portal hypertension. Although guidelines recommend endoscopic screening for varices, proposed standardized management in this population is lacking. Therefore, this study investigates prevention and treatment strategies based on expert opinion.

Methods

This study encompasses an online survey distributed to hepatologists and medical oncologists in Dutch and Belgian HCC expertise centers. The primary aim was to gather experts’ insights into current clinical practice for the prevention and management strategies of both varices and variceal bleeding in HCC patients receiving systemic therapy.

Results

A total of 35 respondents completed the survey, of whom 97% consider the potential presence of varices before initiating atezolizumab-bevacizumab in patients with underlying cirrhosis, using gastroscopy (55%) or following Baveno VII criteria (36%). In case of low-risk varices, 82% of respondents would start a non-selective beta-blocker (NSBB) before initiating atezolizumab-bevacizumab and 55% before a tyrosine kinase inhibitor. For high-risk varices, 44% opt to start atezolizumab-bevacizumab after NSBB initiation, in combination with complete eradication of varices using endoscopic band ligation. Different approaches among specialists became apparent.

Conclusions

This study demonstrates heterogeneity in variceal screening and prophylactic strategies among HCC specialists. This variability reflects the lack of evidence-based guidance and may affect treatment safety and efficacy, which calls for standardized approaches to optimize bleeding risk management in this population.

Zitieren

APA

Trombosi, S. I. D. E. E. (2026). PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE. Bleeding, Thrombosis and Vascular Biology, 5(s1). https://doi.org/10.4081/btvb.2026.554

Vancouver

Trombosi SIDEE. PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE. Bleeding, Thrombosis and Vascular Biology. 2026;5(s1). doi:10.4081/btvb.2026.554

BibTeX
@article{Trombosi2026,
  author = {Trombosi, Società Italiana di Emostasi e},
  title = {PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE},
  journal = {Bleeding, Thrombosis and Vascular Biology},
  year = {2026},
  volume = {5},
  number = {s1},
  doi = {10.4081/btvb.2026.554}
}
Kostenlos starten →